NCT05577000View on ClinicalTrials.gov

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

October 31, 2028

Study Completion Date

October 1, 2043

Conditions
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Interventions
BIOLOGICAL

Manufactured Anti-BCMA CAR-T cells

Given IV

DRUG

Fludarabine

Given IV

DRUG

Cyclophosphamide

Given IV

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Actavis Inc.
All Listed Sponsors
collaborator

Actavis Inc.

INDUSTRY

collaborator

University of California, Davis

OTHER

collaborator

Eugia Pharma Specialities Limited

UNKNOWN

lead

Thomas Martin, MD

OTHER